Advances in malignant glioma drug discovery

被引：13
作者：
Reardon, David A. [1 ,2 ]
Perry, James R. [3 ]
Brandes, Alba A. [4 ]
Jalali, Rakesh [5 ]
Wick, Wolfgang [6 ]
机构：
[1] Duke Univ, Med Ctr, Dept Surg, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Pediat, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurol & Med Oncol, Toronto, ON, Canada
[4] Bellaria Maggiore Hosp, Dept Med Oncol, Azienda Unita Sanit Locale Bologna, Bolongna, Italy
[5] Tata Mem Hosp, Dept Radiat Oncol, Bombay 400012, Maharashtra, India
[6] Heidelberg Univ, Dept Neurooncol, German Canc Res Ctr, Heidelberg, Germany
来源：
EXPERT OPINION ON DRUG DISCOVERY | 2011年 / 6卷 / 07期
关键词：
angiogenesis; EGFR; glioblastoma; integrins; malignant glioma; temozolomide; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB PLUS IRINOTECAN; HIGH-GRADE GLIOMAS; INTEGRATED GENOMIC ANALYSIS; HEDGEHOG SIGNALING PATHWAY; TYROSINE KINASE INHIBITOR; PROGRESSION-FREE SURVIVAL; SINGLE-AGENT BEVACIZUMAB;
D O I：
10.1517/17460441.2011.584530
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review describes three foci of advanced clinical research aimed at improving the outcome of GBM patients: protracted temozolomide dosing, VEGF-inhibiting agents and integrin inhibitors. This review also discusses potential clinical trial strategies to evaluate irreversible EGFR inhibitors as well as therapeutics targeting PI3K and the hedgehog signaling pathway. Expert opinion: Several factors limit the efficacy of therapeutics targeting GBM. However, significant advances from basic science laboratories have recently generated important insights into the pathophysiology and molecular genetic abnormalities of these tumors. Efforts to translate these findings into innovative treatment strategies offer substantial promise to overcome therapeutic hurdles and treat individual patients more effectively. Improved understanding of malignant glioma biology and factors associated with treatment response will probably lead to improved therapeutic options and a better patient outcome.
引用
收藏
页码：739 / 753
页数：15
相关论文
共 210 条
  • [1] Integrin αVβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models
    Albert, Jeffrey M.
    Cao, Carolyn
    Ling Geng
    Leavitt, Lauren
    Hallahan, Dennis E.
    Bo Lu
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (05): : 1536 - 1543
  • [2] [Anonymous], P AM SOC CLIN ONC 20
  • [3] [Anonymous], 2004, GLOBOCAN 2002 CANC I
  • [4] [Anonymous], P AM SOC CLIN ONC 20
  • [5] [Anonymous], CBTRUS 2010 STAT REP
  • [6] [Anonymous], WORLD FED NEUR M 5 8
  • [7] [Anonymous], P AM SOC CLIN ONC 20
  • [8] [Anonymous], P SOC NEUR 2007 DALL
  • [9] [Anonymous], P AM SOC CLIN ONC 20
  • [10] [Anonymous], J NEUROONCOL
12345678910